BDNF and Mental deterioration: In our previous clinical studies, we observed that breast cancer patients [3, 12] receiving doxorubicin and cyclophosphamide reported self-perceived concentration deficits during chemotherapy, and patients experiencing the least reduction of plasma BDNF levels between baseline and end of chemotherapy were most protected from cognitive decline.